Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01969643
Title A Safety Study of SGN-LIV1A in Breast Cancer Patients
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Seattle Genetics, Inc.
Indications

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

Therapies

Ladiratuzumab vedotin

Ladiratuzumab vedotin + Trastuzumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.